38 results about "Antipsychotic drug" patented technology

The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.

The invention relates to a preparation method of an antipsychotic drug olanzapine. The method comprises three steps: first, using sulfur, propionaldehyde and malononitrile as raw materials, triethylamine as a catalyst to carry out ringclosure to obtain 5-methyl-2-amino-3-cyanothiophene; second, the 5-methyl-2-amino-3-cyanothiophene and o-fluoronitrobenzene generating 5-methyl-2-(2- nitrophenylamino)-3-cyanothiophene under effects of sodium hydride; third, the 5-methyl-2-(2- nitrophenylamino)-3-cyanothiophene reacting with hydrazine hydrate and N-methyl piperazine to carry out ringclosure reaction under existence of ferric trichloride / active carbon catalyst; so as to generate objective compound olanzapine through a one-pot method. The invention has the advantages of cheap and easily available raw materials, few steps, and simple process. A one-pot reaction is carried out in the third step, so that intermediate state compounds during the reaction process do not need to be separated or removed and can converse into the objective compound, and the high-purity olanzapine can be obtained with high yield. The whole process is suitable for industrial mass production with high product yield, low costs and convenient post-treatment.

An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug to a patient intranasally using an intranasal metered dose sprayer. A method of treating a psychotic episode also is provided, the method including the step of delivering an antipsychotic drug, such as haloperidol, intranasally in an amount effective to control the psychotic episode.

The invention discloses a multiple gene detection kit for guiding antipsychotic drugs and a using method thereof. The kit adopts multiple PCR combined with a fragment length/mass analysis method and synchronously and qualitatively detects 7 nucleotide polymorphism (SNP) locus on 6 genes including CYP2D6, MC4R, CYP1A2, CYP3A5, EPM2A, and SLC6A2 which are related to antipsychotic drug metabolism, transport and target action. The method comprises the detection steps of (1) collecting oral exfoliated cells and storing on a cell collection card or collecting blood samples and extracting nucleic acids; (2) performing multiple PCR amplification using the cell collection card or nucleic acid as described in step 1 as formwork; (3) according to PCR product fragment length/mass, simultaneously separating into 7 SNP loci, 3 human DNA internal reference genes and 1 PCR reaction internal reference PCR product; (4) analyzing results and interpreting. The kit has the advantages of fast performance, high sensitivity, good repeatability, strong specificity, high throughput and low cost.

The invention provides use and preparation method of pinosylvin. The pinosylvin is used for preparing a medicine for inhibiting nerve activity, and is also used for preparing an antipsychotic drug. Itis found through the study of the pinosylvi that the pinosylvi has a strong function of blocking the activation of a nerve signal transduction system, and further experiments prove that the pinosylvicrystal can be specifically combined with a neuron and a strong neural inhibition effect occurs.

The invention provides an antipsychotic drug related metabolism syndrome susceptible gene and an application thereof, and concretely relates to a use of a separate single-nucleotide polymorphism (SNP) site-containing polynucleotide or a detection reagent thereof in the preparation of kits for detecting antipsychotic drug related metabolism syndrome susceptibility. The SNP site in the polynucleotide corresponds to human chromosome 17p11.2 region (chr17:17708129(GRCh37/hg19)), rs11654081, C to T. The susceptibility of individuals to antipsychotic drug related metabolism syndrome can be judged in an adjuvant manner through detecting the gene and SNP, and a new approach is provided for diagnosis and corresponding treatment of the syndrome; and additionally, the discovery of the gene and the SNP also provides a new drug target for developing drugs for treating the related metabolism syndrome, and the gene and the SNP can be used as syndrome patient regression and prognosis molecule markers.

The invention relates to a method for preparing a benzisoxazole antipsychotic drug risperidone and belongs to the technical field of preparation of risperidone. The method for preparing a benzisoxazole antipsychotic drug risperidone comprises the following step of carrying out cyclization reaction on (z)-[3-[4-[(2,4-difluorophenyl)methyloximido]piperidinyl]-1-ethyl]-2-methyl-6,7,8,9-4H-pyridino[1,2-a]pyrimidin-4-one serving as a starting material in a mixed solvent of dichloromethane and concentrated alkali water to prepare the target product risperidone. The method is simple in operation and low in requirements on the device, the prepared product is high in purity and is suitable for industrial production.

Provided herein are methods of treatment of psychiatric disorders requiring treatment with an antipsychotic drug, such as schizophrenia or schizoaffective disorder, comprising administration of both the antipsychotic drug and a W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof to treat symptoms of the psychiatric disorder. Treatment is typically continued for at least four weeks. A combination dosage form comprising both the antipsychotic drug and the W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof in amounts effective to treat the psychiatric disorder.

The present invention relates to a pharmaceutical composition comprising at least one liposome and an antipsychotic drug with a high drug to lipid ratio and encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the antipsychotic drug. Also provided is the method for treating schizophrenia or bipolar disorder using the pharmaceutical composition disclosed herein.

Electronic devices and methods are provided for the treatment of schizophrenia utilizing delivery of an antipsychotic in combination with computerized behavioral therapy.

The present invention is concerned with a modified release pharmaceutical composition comprising an effective amount of at least one antipsychotic agent so that the antipsychotic agent(s) are released in such a manner to better accord with physiological and chronotherapeutic requirements of patients.

4-amino-5-thiophenol-2-methoxymethyl benzoate is an important intermediate of the antipsychotic drug amisulpride. The invention relates to a preparation method of 4-amino-5-thiophenol-2-methoxymethylbenzoate. The method is mild in reaction conditions, easy to operate and simple in purification process.

An antipsychotic and GlyT1 inhibitor combination is disclosed. The antipsychotic and GlyT1 inhibitor combination may be employed in the prevention and treatment of symptoms of schizophrenia. Pharmaceutical compositions and treatments comprising an antipsychotic and a GlyT1 inhibitor for treating symptoms of schizophrenia are thus also disclosed.

An object of the present invention is to provide a novel therapeutic agent for a mental disorder with abnormal neurodevelopment as a pathological condition. The present invention provides an antipsychotic drug containing a Rho kinase inhibitor as an active ingredient. The antipsychotic drug can be used, for example, in the treatment of schizophrenia, autism spectrum disorder, bipolar disorder, or depression.

The invention belongs to the field of traditional Chinese medicines and discloses a traditional Chinese medicine decoction for treating amenorrhea caused by antipsychotic drugs, particularly both-Qi-and-blood deficiency type amenorrhea. According to the traditional Chinese medicine decoction, gymnadnia conopsear, Potentilla anserina, rhizoma polygonati, carex cruciata, Manglietia szechuanica, Leycesteria formosa, Circaea lutetiana, Diversifolious hemiphragma, Balanophora polyandra, arachnoid cyanotis roots, magnetite, glycyrrhiza uralensis and the like are picked as raw pharmaceutical materials according to pathogeny and pathogenesis of this disease. According to the traditional Chinese medicine decoction, the prescription is concise and rigorous and is linked together with the pathogenesis, and the whole prescription has the effects of replenishing Qi and blood, strengthening the spleen and harmonizing the stomach, nourishing blood and regulating menstruation, promoting the flow of Qi by warming the channel and tranquilizing and allaying excitement. The traditional Chinese medicine decoction disclosed by the invention is free of side effect and is applicable to the amenorrhea caused by different antipsychotic drugs, the absorption of the antipsychotic drugs is not affected, and the traditional Chinese medicine decoction is free of antagonistic action on the antipsychotic drugs taken by patients and can also exert the effects of soothing nerves and calming in an auxiliary manner, so that the dependence of the patients on taking of the antipsychotic drugs is improved. The clinical total effective rate reaches 94.74%, so that the traditional Chinese medicine decoction is worthy of clinical popularization.